Skip to main content

Daiichi Sankyo Establishes Two Research Institutes in the U.S. and EU

Written by: Editor
Published on: 23 May 2024

Daiichi SankyoTokyo - (May 22, 2024) - Daiichi Sankyo (TSE: 4568) has established two research institutes: DS Research Institute Boston and DS Research Institute Munich, in Cambridge, Massachusetts, U.S. and Munich, Germany, respectively. Daiichi Sankyo plans to initiate operations in both locations by September 2024 to build new, and deepen existing, partnerships in these world-renowned innovation hotspots toward the common goal of bringing medical innovation to patients. By continued collaboration with other companies, universities, research institutions, and startups, Daiichi Sankyo aims to foster new innovative ideas and technologies as well as incorporate them, in alignment with the strategy of identifying new growth drivers to enhance the company’s drug discovery function.

"The establishment of our research institutes in Cambridge and Munich marks an important step to solidify our presence in the global drug discovery ecosystem," said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “By enhancing our presence in these regions and utilizing our strengths in science and technology, Daiichi Sankyo will continuously generate innovation through further collaborations with business partners and academia, contributing to the enrichment of quality of life around the world.”

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit

Media Contacts:


Daiichi Sankyo Co., Ltd.

Investor Relations Contact: